Kyntra Bio, Inc.
KYNB
Positions held
Your positionsKYNB isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $24.13M | Enterprise value | -$45.19M | Trailing P/E | — | Forward P/E | -0.42 |
| PEG | — | Price / book | -0.80 | Beta | 1.05 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 11.9% |
| Profit margin | 39.7% | ROE | — | ROA | -22.5% | Debt / equity | — |
| Current ratio | 2.69 | Free cash flow | $54.07M | Analyst recommendation | none | Mean target | $39.67 |
| 52w high | $11.65 | 52w low | $5.62 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | -$1.5M | $3.7M | $1.3M | $1.1M | $1.3M |
| Op margin | 1191.5% | -369.1% | -1058.7% | -499.1% | -864.9% |
| Net income | $12.0M | -$15.2M | -$14.2M | $201M | -$7.6M |
| Gross margin | 100.1% | -9.8% | 78.2% | 105.4% | 93.7% |
| Gross profit | -$1.5M | -$0.4M | $1.0M | $1.1M | $1.3M |
| Operating income | -$17.6M | -$13.8M | -$13.5M | -$5.4M | -$11.7M |
- Revenue -139% vs prior quarter (-$1.5M vs $3.7M).
- Gross margin 100.1% (was -9.8% prior quarter).
- Operating margin expanded to 1191.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.4M | $29.6M | $46.8M | $141M | — |
| Op margin | -704.1% | -442.1% | -662.6% | -213.9% | — |
| Net income | $183M | -$47.6M | -$284M | -$294M | — |
| Gross margin | 91.4% | 47.5% | 91.5% | 85.6% | — |
| Gross profit | $5.9M | $14.1M | $42.8M | $120M | — |
| Operating income | -$45.3M | -$131M | -$310M | -$301M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
2026-09-18 · Lake Street Initiates Kyntra Bio at Buy With $41 Price Target
2026-09-02 · Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-31 · Kyntra Bio Cuts Royalty Payments to NQ Project Phoebus for Accelerated Upfront Payment
2026-08-31 · Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation
2026-08-20 · Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript
2026-08-17 · Kyntra Bio Inc (KYNB) (Q2 2026) Earnings Call Highlights: Advancing FG-3246 and Roxadustat with ...
2026-08-13 · Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates
2026-08-13 · Kyntra Bio: Q2 Earnings Snapshot
2026-08-12 · Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimates
2026-08-06 · Kyntra Bio to Report Second Quarter 2026 Financial Results
2026-08-03 · Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?
Price (daily)
Full chart · RSI · MACD · patterns